Patents by Inventor Atsushi Izawa
Atsushi Izawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220007496Abstract: An optical module includes a box-shaped housing with an optical element mounted therein. Further, a wiring substrate is bonded to a part of a surface of a housing part of the housing, and an electric wiring, which is formed in the wiring substrate or on a surface of the wiring substrate, and an electric wiring, which is introduced into the housing part or onto a surface of the housing part, are electrically connected to each other.Type: ApplicationFiled: September 17, 2021Publication date: January 6, 2022Applicant: FURUKAWA ELECTRIC CO., LTD.Inventors: Maiko ARIGA, Yusuke INABA, Kazuki YAMAOKA, Atsushi IZAWA, Kazuya NAGASHIMA
-
Publication number: 20210376931Abstract: An optical module includes: photoelectric elements including first terminal groups; an integrated circuit including second terminal groups and ground terminals; a carrier substrate; a housing; and a common ground pad. Further, the carrier substrate is fixed to one surface of the housing, the carrier substrate includes signal wiring parts and a ground wiring part, the ground wiring part includes terminal pattern parts, a common pattern part, and a coupling part, each of the terminal pattern parts being disposed between the corresponding signal wiring parts and electrically connected with one of the ground terminals, the common pattern part being disposed on a side where the common ground pad is provided on the carrier substrate, the coupling part electrically connecting each terminal pattern part and the common pattern part, and the ground terminals of the integrated circuit are electrically connected with the common ground pad through the ground wiring part.Type: ApplicationFiled: August 12, 2021Publication date: December 2, 2021Applicant: FURUKAWA ELECTRIC CO., LTD.Inventors: Kazuya NAGASHIMA, Yozo ISHIKAWA, Atsushi IZAWA
-
Publication number: 20210320719Abstract: An optical module includes: a laser device; a wavelength detector; a modulator; a modulator driver; a coherent mixer; a photoelectric element; a transimpedance amplifier; and a casing. Further, the laser device is arranged such that the laser device outputs a laser light beam in a direction opposite to a side on which the optical output unit is arranged in the casing.Type: ApplicationFiled: June 23, 2021Publication date: October 14, 2021Applicant: FURUKAWA ELECTRIC CO., LTD.Inventors: Kazuya NAGASHIMA, Yozo ISHIKAWA, Atsushi IZAWA, Kazuki YAMAOKA
-
Publication number: 20170261701Abstract: An optical module includes a first module having a first end surface provided with a first guide hole and a second end surface opposite the first end surface, wherein the first module includes first optical fibers each provided penetrating the first module from the first end surface to the second end surface and having an axial center aligned based on a positional relationship to the first guide hole, and a first optical element having an axial center aligned based on a positional relationship to the first guide hole.Type: ApplicationFiled: May 30, 2017Publication date: September 14, 2017Applicant: FURUKAWA ELECTRIC CO., LTD.Inventor: Atsushi IZAWA
-
Patent number: 9725514Abstract: The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.Type: GrantFiled: January 23, 2008Date of Patent: August 8, 2017Assignees: Shinshu University, Chugai Seiyaku Kabushiki KaishaInventors: Masafumi Takahashi, Atsushi Izawa
-
Patent number: 9562103Abstract: The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.Type: GrantFiled: January 23, 2008Date of Patent: February 7, 2017Assignees: Chugai Seiyaku Kabushiki Kaisha, Shinshu UniversityInventors: Masafumi Takahashi, Atsushi Izawa
-
Patent number: 8623355Abstract: The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.Type: GrantFiled: November 15, 2006Date of Patent: January 7, 2014Assignees: Chugai Seiyaku Kabushiki Kaisha, National Hospital Organization, Shinshu UniversityInventors: Masaji Okada, Masafumi Takahashi, Atsushi Izawa, Yoshiyuki Ohsugi, Masahiko Mihara
-
Publication number: 20100061986Abstract: The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.Type: ApplicationFiled: January 23, 2008Publication date: March 11, 2010Applicants: Shinshu University, Chugai Seiyaku Kabushiki KaishaInventors: Masafumi Takahashi, Atsushi Izawa
-
Publication number: 20090263384Abstract: The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.Type: ApplicationFiled: November 15, 2006Publication date: October 22, 2009Applicants: NATIONAL HOSPITAL ORGANIZATION, SHINSHU UNIVERSITY, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Masaji Okada, Masafumi Takahashi, Atsushi Izawa, Yoshiyuki Ohsugi, Masahiko Mihara
-
Publication number: 20090032984Abstract: A method for manufacturing optical fibers with filter, wherein a multilayer-film filter is formed at end face of the optical fibers, comprising a process for fixing each of the optical fibers on a fixing jig, a process for polishing the end face of the optical fiber fixed on said fixing jig, a process for film-forming a filter on the end face of the optical fibers after polishing, and a process for taking out said optical fibers from said fixing jigs, respectively, wherein said process for film-forming the filter is performed by forming a fiber bundle in which a plural number of optical fibers after polishing, on which the filter has been film-formed, are tied such that all polished planes are aligned at the end face.Type: ApplicationFiled: July 9, 2008Publication date: February 5, 2009Applicant: THE FURUKAWA ELECTRIC CO., LTD.Inventors: Masayuki Iwase, Atsushi Izawa, Yozo Ishikawa
-
Patent number: 7412148Abstract: An optical component provided with a waveguide groove having, an waveguide holding plane having a surface shape extending along a specified axial direction and capable of holding at least one optical waveguide while positioning it at at least a part of at least one side face thereof; and an opening extending substantially oppositely to the waveguide holding plane and being smaller in width than the outside diameter of at least one optical waveguide in a specified widthwise direction perpendicular to the specified axial direction.Type: GrantFiled: October 17, 2003Date of Patent: August 12, 2008Assignee: The Furukawa Electric Co., Ltd.Inventors: Masayuki Iwase, Atsushi Izawa, Yozo Ishikawa
-
Patent number: 6608725Abstract: An optical module, in which an optical device can be mounted and repaired without damaging an electrode on an electronic device side, is provided. A photodiode (1) and a pre-amplifier IC (2) are mounted on a base (stem) (4), and except for that, a relay terminal table (7) is provided. The photodiode (1) and the pre-amplifier IC (2) are connected through the relay terminal table (7) by means of bonding wires (3a, 3b). The relay terminal table (7) is connected via the bonding wire (3a) to an electrode (11) of the photodiode (1), as well as via the bonding wire (3b) to an electrode (12) of the pre-amplifier IC (2). In repairing the photodiode (1) only the bonding wire (3a) is removed for re-wiring, so that the electrode (12) of the pre-amplifier IC can be prevented from being damaged.Type: GrantFiled: June 26, 2001Date of Patent: August 19, 2003Assignee: The Furukawa Electric Co., Ltd.Inventors: Atsushi Izawa, Masayuki Iwase
-
Patent number: 6552083Abstract: The present invention relates to an agent for inhibiting diseases associated with chronic rejection after organ transplantation, such as transplanted heart-accelerated coronary arteriosclerosis, containing as an active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by formula: or a pharmaceutically acceptable salt thereof, which has an inhibitory effect on vascular thickening in transplanted hearts.Type: GrantFiled: May 23, 2002Date of Patent: April 22, 2003Assignee: Kissei Pharmaceutical Co., Ltd.Inventors: Mitsuaki Isobe, Atsushi Izawa
-
Publication number: 20020067554Abstract: An optical module, in which an optical device can be mounted and repaired without damaging an electrode on an electronic device side, is provided. A photodiode (1) and a pre-amplifier IC (2) are mounted on a base (stem) (4), and except for that, a relay terminal table (7) is provided. The photodiode (1) and the pre-amplifier IC (2) are connected through the relay terminal table (7) by means of bonding wires (3a, 3b). The relay terminal table (7) is connected via the bonding wire (3a) to an electrode (11) of the photodiode (1), as well as via the bonding wire (3b) to an electrode (12) of the pre-amplifier IC (2). In repairing the photodiode (1) only the bonding wire (3a) is removed for re-wiring, so that the electrode (12) of the pre-amplifier IC can be prevented from being damaged.Type: ApplicationFiled: June 26, 2001Publication date: June 6, 2002Inventors: Atsushi Izawa, Masayuki Iwase